ERBB2 and breast carcinoma: The adoption of biomarker measurement, such as for estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor 2 (HER2), ushered in a new era of breast cancer treatment, with an individual patient’s biomarker profile helping to guide their treatment [3].